An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy

Mayo Clinic Proceedings

Volumn 85, Issue 4, 2010, Pages 341-348

  Caplan, Liron ^a   Pittman, Cory B ^b   Zeringue, Angelique L ^c   Scherrer, Jeffrey F ^c   Wehmeier, Kent R ^d   Cunningham, Francesca E ^e   Eisen, Seth A ^f   Mcdonald, Jay R ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Mercy Arthritis and Osteoporosis Center   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e Veterans Affairs Pharmacy Benefits Management   (United States)

^f VA Health Services Research and Development Service   (United States)

Author keywords

HMG CoA = 3 hydroxy 3 methylglutaryl coenzyme A; HR = hazard ratio; ICD 9 CM = International Classification of Diseases, Ninth Revision, Clinical Modification; MSKP = musculoskeletal pain; OR = odds ratio; VA = US department of veterans affairs

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

AGED; ANXIETY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; FEMALE; HIP FRACTURE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; MYALGIA; OSTEOPOROSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL ANALYSIS; VERTEBRA FRACTURE; VETERAN;

EID: 77950604313     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0492     Document Type: Article

References (29)

1. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90(90):107-110.
2. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005; 16 (suppl 2) : S3-S7.
3. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12(12):24-35.
4. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14(14):965-968.
5. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W. The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMCMusculoskelet Disord. 2007 Sep. 26;8:97.
6. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17(17):1645-1652.
7. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(21):1453-1460.
8. Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int. 2007;18(18):1421-1427.
9. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165(165):346-347.
10. Bock O, Boerst H, Thomasius FE, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact. 2007;7(7):144-148.
11. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(356):1809-1822.
12. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON) : a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(373):1253-1263.
13. US Food and Drug Administration. FDA MedWatch Safety Alert Web site. Information for healthcare professionals: bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm101551.htm. Published January 7, 2008. Accessed January 29, 2010.
14. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83(83):687-700.
15. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154(154):854-864.
16. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003;38(38):1103-1120.
17. Department of Veterans Affairs; Veterans Health Administration. Pain management. VHA Directive 2003-021. http://www1.va.gov/pain-management/docs/ VHAPainDirective-03.pdf. Published May 2, 003. Accessed January 29, 2010.
18. VA Information Resource Center (VIReC) Web site. http://www.virec. research.va.gov/Support/Training-NewUsersToolkit/IntroToVAData.htm.)
19. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res. 2002;11(11):68-74.
20. Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol. 2006;33(33):1651-1657.
21. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int. 2005;16(16):2168-2174.
22. Duyvendak M, Naunton M, Atthobari J, van den Berg PB, Brouwers JR. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in the Netherlands 2001-2005. Osteoporos Int. 2007;18(18):1429-1433.
23. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002; (2) : CD002068.
24. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(353):898-908.
25. Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Clin Ther. 2001;23(23):620-626.
26. Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol. 1999;18(18):266-267.
27. Diaz-Borjon A, Seyler TM, Chen NL, Lim SS. Bisphosphonate-associated arthritis. J Clin Rheumatol. 2006;12(12):131-133.
28. Haegerstam GA. Pathophysiology of bone pain: a review. Acta Orthop Scand. 2001;72(72):308-317.
29. Kressin NR, Chang BH, Hendricks A, Kazis LE. Agreement between administrative data and patients' self-reports of race/ethnicity. Am J Public Health. 2003;93(93):1734-1739.